PARP inhibition potentiated platinum cytotoxicity in the O-342/DDP and CH1cisR platinum-resistant ovarian cancer cell lines [31, 32], as well as in the BRCAwt and BRCA2-restored OV90 and PEO4 ovarian cancer cell lines, respectively [33]. This evidence concerns the gene BRCA2 and ovarian carcinoma.